Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex's Q3 update could have made some investors at least a little more nervous. However, there are four reasons some might be concerned that are easily debunked.

4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked

Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.

Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q3 2023 Earnings Call Transcript November 6, 2023 4:30 PM ET Company Participants Susie Lisa - CFA, Senior Vice President of Investor Relations Reshma Kewalramani - President & Chief Executive Officer Stuart Arbuckle - Executive Vice President & Chief Operating Officer Charlie Wagner - Executive Vice President & Chief Financial Officer Conference Call Participants Geoff Meacham - Bank of America Robyn Karnauskas - Truist Securities Salveen Richter - Goldman Sachs Phil Nadeau - TD Cowen Mohit Bansal - Wells Fargo Jessica Fye - JPMorgan David Risinger - Leerink Partners Evan Seigerman - BMO Capital Markets Liisa Bayko - Evercore ISI Michael Yee - Jefferies Terence Flynn - Morgan Stanley Operator Good day and welcome to the Vertex Pharmaceuticals Third Quarter 2023 Conference Call. All participants will be in a listen only mode.

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2023 Earnings Call Transcript

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.92 per share. This compares to earnings of $4.01 per share a year ago.

Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings Estimates

Vertex Pharmaceuticals missed Wall Street estimates for third-quarter sales on Monday, hurt by weaker-than-expected demand for its older cystic fibrosis (CF) treatments.

Vertex Pharma misses sales estimates on weak demand for older CF treatments

Late Monday, Vertex reported adjusted earnings of $4.08 per share on $2.48 billion in third-quarter sales. In response, VRTX stock slipped.

IBD Tech Leader Vertex Boosts Outlook After Strong Earnings

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2023, raised full year 2023 guidance for product revenue and reiterated full year 2023 guidance for operating expenses. “Vertex has delivered another strong quarter across the business. We remain relentless in our commitment to reach more patients with our cystic fibrosis medicines, while preparing for the potential launch of exa-cel.

Vertex Reports Third Quarter 2023 Financial Results

Young English sufferers of cystic fibrosis (CF) face new uncertainty after regulators published proposals which, if enacted, would restrict access to potentially life-changing treatments on cost grounds.

England's young cystic fibrosis patients face new treatment worry

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is It Worth Investing in Vertex (VRTX) Based on Wall Street's Bullish Views?

CRISPR Therapeutics

Vertex Pharmaceuticals and CRISPR Therapeutics just met with regulators at the Food and Drug Administration. The discussion was about the safety of their gene therapy candidate called exa-cel.

Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $376.55, representing a +1.95% change from its previous close.

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that seven abstracts have been accepted for presentation at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition. This includes two presentations of updated clinical data describing additional patients with longer follow-up duration from pivotal Phase 3 trials investigating exagamglogene autotemcel's (exa-cel) potential as a one-time functional cure for sickle cell disease (SCD) an.

Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat the underlying cause of cystic fibrosis (CF) in ~90% of people with the disease, will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) taking place November 2-4, 2023 in Phoenix, Arizona. Presentations will highlight results from two open-label extension studies demonstrating the long-term c.

Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference

A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals and CRISPR Therapeutics could assess potential safety risks of their sickle cell disease gene therapy after approval.

FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study

The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.

Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients

Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease.

FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy?

Chevron

Microsoft

AbbVie

Advanced Micro Devices

Bristol-Myers

Comcast

Cisco Systems

Datadog

L3Harris

Southwest Airlines

Newell Brands

ON Semiconductor

Sanofi

Valley National

Western Digital

Here are some of the tickers on Jim's radar for Monday, Oct. 30, taken directly from his reporter's notebook:

Here are 16 stocks Jim Cramer is watching, including Microsoft, Chevron, Southwest

Amgen

bluebird bio

Editas Medicine

Regeneron Pharmaceuticals

The Food and Drug Administration will hold an advisory committee meeting for the first CRISPR/Cas9 gene-edited product candidate this week. If approved, CRISPR Therapeutics and Vertex Pharmaceuticals' sickle cell disease therapy could generate blockbuster sales figures.

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient

Brookfield Renewable Partners

Transmedics Group Inc

Vertex Pharmaceuticals' pipeline should enable the biotech to deliver explosive growth. TransMedics Group is disrupting a huge -- and rapidly growing -- market.

Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade

Intuitive Surgical

Healthcare businesses with wide moats and competitive advantages are compelling in any market. Vertex has several promising irons in the fire -- on top of an already profitable business.

2 Top Healthcare Stocks Defying the Bear Market

Large-cap growth stocks with wide economic moats and top-shelf management teams have outperformed this year. Vertex Pharmaceuticals, a rare disease specialist, has been one of the strongest performers within the group.

This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024

DexCom

The stock market may be volatile, but investors don't have to wait on the sidelines. Vertex Pharmaceuticals is forging its own path in the rare disease drug market.

2 Best Healthcare Stocks to Buy Right Now

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charles Wagner, Executive Vice President and Chief Financial Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer, will participate in a fireside chat at UBS Biopharma Conference on Thursday, November 9, 2023 at 12:00 p.m. ET. Stuart Arbuckle, Executive Vice President and Chief Ope.

Vertex to Present at Upcoming Investor Conferences

Vertex is firing on all cylinders, with its billion-dollar cystic fibrosis business booming and its pipeline programs advancing. The company may be about to reach a big milestone: the potential regulatory approval of a product in a new treatment area.

News for Vertex Pharmaceuticals Stock (VRTX)